JP5290954B2 - スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用 - Google Patents
スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用 Download PDFInfo
- Publication number
- JP5290954B2 JP5290954B2 JP2009502912A JP2009502912A JP5290954B2 JP 5290954 B2 JP5290954 B2 JP 5290954B2 JP 2009502912 A JP2009502912 A JP 2009502912A JP 2009502912 A JP2009502912 A JP 2009502912A JP 5290954 B2 JP5290954 B2 JP 5290954B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- mmol
- hydrogen
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037259 Amyloid Plaque Diseases 0.000 title claims abstract description 39
- BIAWAXVRXKIUQB-UHFFFAOYSA-N 2-(2-phenylethenyl)pyridine Chemical class C=1C=CC=CC=1C=CC1=CC=CC=N1 BIAWAXVRXKIUQB-UHFFFAOYSA-N 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 165
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000003384 imaging method Methods 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- 239000001257 hydrogen Substances 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 230000003941 amyloidogenesis Effects 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract description 7
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000002776 aggregation Effects 0.000 abstract description 3
- 238000004220 aggregation Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 58
- -1 R 31 Chemical compound 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 150000002431 hydrogen Chemical class 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- 208000024827 Alzheimer disease Diseases 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- 229910052736 halogen Inorganic materials 0.000 description 34
- 150000002367 halogens Chemical class 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 210000004556 brain Anatomy 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 26
- 239000003446 ligand Substances 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- 125000003545 alkoxy group Chemical group 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 230000002285 radioactive effect Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 239000000700 radioactive tracer Substances 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229940056501 technetium 99m Drugs 0.000 description 7
- YTRHFRDQQSDDRB-OWOJBTEDSA-N 2-[2-[2-[5-[(e)-2-(4-aminophenyl)ethenyl]pyridin-2-yl]oxyethoxy]ethoxy]ethanol Chemical compound C1=CC(N)=CC=C1\C=C\C1=CC=C(OCCOCCOCCO)N=C1 YTRHFRDQQSDDRB-OWOJBTEDSA-N 0.000 description 6
- BRHSFMBLRMVBBH-OWOJBTEDSA-N 2-[2-[2-[5-[(e)-2-(4-nitrophenyl)ethenyl]pyridin-2-yl]oxyethoxy]ethoxy]ethanol Chemical compound C1=NC(OCCOCCOCCO)=CC=C1\C=C\C1=CC=C([N+]([O-])=O)C=C1 BRHSFMBLRMVBBH-OWOJBTEDSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000005977 Ethylene Substances 0.000 description 6
- 229910052770 Uranium Inorganic materials 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 5
- SSZYZLZGRCUYIK-UHFFFAOYSA-N 2-[2-(2-fluoroethoxy)ethoxy]ethanol Chemical compound OCCOCCOCCF SSZYZLZGRCUYIK-UHFFFAOYSA-N 0.000 description 5
- YLIQZVBYENYHGM-OWOJBTEDSA-N 2-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-5-[(e)-2-(4-nitrophenyl)ethenyl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C1=CC=C(OCCOCCOCCF)N=C1 YLIQZVBYENYHGM-OWOJBTEDSA-N 0.000 description 5
- RMVDTGLZMNQRAH-ONEGZZNKSA-N 2-[2-[2-[5-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]pyridin-2-yl]oxyethoxy]ethoxy]ethanol Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=CC=C(OCCOCCOCCO)N=C1 RMVDTGLZMNQRAH-ONEGZZNKSA-N 0.000 description 5
- RDZUORKQODTGFP-VOTSOKGWSA-N 2-[2-[2-[5-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]pyridin-2-yl]oxyethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C(C=N1)=CC=C1OCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 RDZUORKQODTGFP-VOTSOKGWSA-N 0.000 description 5
- YNDIAUKFXKEXSV-UHFFFAOYSA-N 4-[2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-n-methylaniline Chemical compound C1=CC(NC)=CC=C1C=CC1=CC=C(OCCOCCOCCF)N=C1 YNDIAUKFXKEXSV-UHFFFAOYSA-N 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000004104 aryloxy group Chemical class 0.000 description 5
- 125000001231 benzoyloxy group Chemical class C(C1=CC=CC=C1)(=O)O* 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 239000001119 stannous chloride Substances 0.000 description 5
- 235000011150 stannous chloride Nutrition 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 210000004885 white matter Anatomy 0.000 description 5
- ZQAQXZBSGZUUNL-BJUDXGSMSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-BJUDXGSMSA-N 0.000 description 4
- DNHVFKKPWZTKCO-OWOJBTEDSA-N 2-chloro-5-[(e)-2-(4-nitrophenyl)ethenyl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C1=CC=C(Cl)N=C1 DNHVFKKPWZTKCO-OWOJBTEDSA-N 0.000 description 4
- GUCOEKKQKHACCX-UHFFFAOYSA-N 3-bromo-5-iodo-1h-pyridin-2-one Chemical compound OC1=NC=C(I)C=C1Br GUCOEKKQKHACCX-UHFFFAOYSA-N 0.000 description 4
- RXNQJSVDHZGXRH-ONEGZZNKSA-N 4-[(e)-2-(6-chloropyridin-3-yl)ethenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=CC=C(Cl)N=C1 RXNQJSVDHZGXRH-ONEGZZNKSA-N 0.000 description 4
- GMDQCFOLABWPEJ-ONEGZZNKSA-N 4-[(e)-2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=CC=C(OCCOCCOCCF)N=C1 GMDQCFOLABWPEJ-ONEGZZNKSA-N 0.000 description 4
- HWDCMGOFOLKQBU-UHFFFAOYSA-N 4-[2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]aniline Chemical compound C1=CC(N)=CC=C1C=CC1=CC=C(OCCOCCOCCF)N=C1 HWDCMGOFOLKQBU-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- XFFSCOOTVXBLCK-QAVVBOBSSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O XFFSCOOTVXBLCK-QAVVBOBSSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 4
- 210000004884 grey matter Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
- 230000004845 protein aggregation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- IAVCEBMLYVGBLA-UHFFFAOYSA-N 2-[1-[6-[2-fluoroethyl(methyl)amino]naphthalen-2-yl]ethylidene]propanedinitrile Chemical compound C1=C(C(C)=C(C#N)C#N)C=CC2=CC(N(CCF)C)=CC=C21 IAVCEBMLYVGBLA-UHFFFAOYSA-N 0.000 description 3
- ZDZHBRNJBKZROL-UHFFFAOYSA-N 3-bromo-2-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-5-iodopyridine Chemical compound FCCOCCOCCOC1=NC=C(I)C=C1Br ZDZHBRNJBKZROL-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- KPMVHELZNRNSMN-UHFFFAOYSA-N chembl1985849 Chemical compound N1=CC=C2NCCN21 KPMVHELZNRNSMN-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 229910052713 technetium Inorganic materials 0.000 description 3
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- JAMNSIXSLVPNLC-UHFFFAOYSA-N (4-ethenylphenyl) acetate Chemical compound CC(=O)OC1=CC=C(C=C)C=C1 JAMNSIXSLVPNLC-UHFFFAOYSA-N 0.000 description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- YLSSVFGTKZXLPA-UHFFFAOYSA-N 2-(1-benzyl-2-ethyl-3-oxamoylbenzo[g]indol-4-yl)oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=C3C=CC=CC3=C2N1CC1=CC=CC=C1 YLSSVFGTKZXLPA-UHFFFAOYSA-N 0.000 description 2
- ZLSRPQOCAMWGCS-UHFFFAOYSA-N 2-(3-bromo-5-iodopyridin-2-yl)oxyethanol Chemical compound OCCOC1=NC=C(I)C=C1Br ZLSRPQOCAMWGCS-UHFFFAOYSA-N 0.000 description 2
- GQWAOUOHRMHSHL-UHFFFAOYSA-N 4-ethenyl-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(C=C)C=C1 GQWAOUOHRMHSHL-UHFFFAOYSA-N 0.000 description 2
- XGOACEXUXLKAFR-UHFFFAOYSA-N 4-ethenyl-n-methylaniline Chemical compound CNC1=CC=C(C=C)C=C1 XGOACEXUXLKAFR-UHFFFAOYSA-N 0.000 description 2
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 2
- AFWWKZCPPRPDQK-UHFFFAOYSA-N 6-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=C(C=O)C=N1 AFWWKZCPPRPDQK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 0 CC(C(*)(*)*)N Chemical compound CC(C(*)(*)*)N 0.000 description 2
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102000012419 Presenilin-2 Human genes 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- VEJXYBLYLRPHPK-UHFFFAOYSA-N [Mo].[Tc] Chemical compound [Mo].[Tc] VEJXYBLYLRPHPK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 229940127206 compound 14d Drugs 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 229910001432 tin ion Inorganic materials 0.000 description 2
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 1
- FZNXRFYRXBFQMX-UHFFFAOYSA-N (4-nitrophenyl)methylphosphonic acid Chemical compound OP(O)(=O)CC1=CC=C([N+]([O-])=O)C=C1 FZNXRFYRXBFQMX-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FORMFFDDQMCTCT-UHFFFAOYSA-N 1-(diethoxyphosphorylmethyl)-4-nitrobenzene Chemical compound CCOP(=O)(OCC)CC1=CC=C([N+]([O-])=O)C=C1 FORMFFDDQMCTCT-UHFFFAOYSA-N 0.000 description 1
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 1
- QGJDXUIYIUGQGO-UHFFFAOYSA-N 1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)N1CCCC1C(O)=O QGJDXUIYIUGQGO-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- WAARUZMZXPJQAM-UHFFFAOYSA-N 2-(3-bromo-5-iodopyridin-2-yl)oxyethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCOC1=NC=C(I)C=C1Br WAARUZMZXPJQAM-UHFFFAOYSA-N 0.000 description 1
- MSSQOQPKGAMUSY-LEAFIULHSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C=CC=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC MSSQOQPKGAMUSY-LEAFIULHSA-N 0.000 description 1
- YSVRVEOTDJVOHH-ONEGZZNKSA-N 2-[3-bromo-5-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]pyridin-2-yl]oxyethanol Chemical group C1=CC(N(C)C)=CC=C1\C=C\C1=CN=C(OCCO)C(Br)=C1 YSVRVEOTDJVOHH-ONEGZZNKSA-N 0.000 description 1
- WFNZNUJABVVFBV-NSCUHMNNSA-N 2-[3-iodo-5-[(e)-2-[4-(methylamino)phenyl]ethenyl]pyridin-2-yl]oxyethanol Chemical group C1=CC(NC)=CC=C1\C=C\C1=CN=C(OCCO)C(I)=C1 WFNZNUJABVVFBV-NSCUHMNNSA-N 0.000 description 1
- ZQAQXZBSGZUUNL-UHFFFAOYSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-UHFFFAOYSA-N 0.000 description 1
- WPWFHGOKCHAUPZ-ONEGZZNKSA-N 2-[5-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]-3-iodopyridin-2-yl]oxyethanol Chemical group C1=CC(N(C)C)=CC=C1\C=C\C1=CN=C(OCCO)C(I)=C1 WPWFHGOKCHAUPZ-ONEGZZNKSA-N 0.000 description 1
- SHQLSTVJDOCJKB-KHLYBYSVSA-N 2-[5-[(e)-2-[4-(methylamino)phenyl]ethenyl]-3-tributylstannylpyridin-2-yl]oxyethanol Chemical group N1=C(OCCO)C([Sn](CCCC)(CCCC)CCCC)=CC(\C=C\C=2C=CC(NC)=CC=2)=C1 SHQLSTVJDOCJKB-KHLYBYSVSA-N 0.000 description 1
- CODBZFJPKJDNDT-UHFFFAOYSA-N 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione Chemical compound CN(C)CCCC1=CN=C(C)C(NC=2N=C3C4=CC=C(C=C4NC(=S)CC3=CN=2)C(F)(F)F)=C1 CODBZFJPKJDNDT-UHFFFAOYSA-N 0.000 description 1
- YJYAGNPMQVHYAH-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethanol Chemical compound CC(C)(C)[Si](C)(C)OCCO YJYAGNPMQVHYAH-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- YDUGVOUXNSWQSW-UHFFFAOYSA-N 3-bromo-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1Br YDUGVOUXNSWQSW-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 1
- DQLFECOUWURYHG-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)-n,n-dimethylaniline Chemical compound CCOP(=O)(OCC)CC1=CC=C(N(C)C)C=C1 DQLFECOUWURYHG-UHFFFAOYSA-N 0.000 description 1
- NYTATACAIMLSHB-OWOJBTEDSA-N 4-[(e)-2-[5-bromo-6-(2-hydroxyethoxy)pyridin-3-yl]ethenyl]phenol Chemical group C1=C(Br)C(OCCO)=NC=C1\C=C\C1=CC=C(O)C=C1 NYTATACAIMLSHB-OWOJBTEDSA-N 0.000 description 1
- WKZBLERDEQCQJQ-OWOJBTEDSA-N 4-[(e)-2-[5-bromo-6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]phenol Chemical group C1=CC(O)=CC=C1\C=C\C1=CN=C(OCCOCCOCCF)C(Br)=C1 WKZBLERDEQCQJQ-OWOJBTEDSA-N 0.000 description 1
- QJJDEUQQBSJKPO-ONEGZZNKSA-N 4-[(e)-2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-5-iodopyridin-3-yl]ethenyl]-n,n-dimethylaniline Chemical group C1=CC(N(C)C)=CC=C1\C=C\C1=CN=C(OCCOCCOCCF)C(I)=C1 QJJDEUQQBSJKPO-ONEGZZNKSA-N 0.000 description 1
- MNFDEPKQRJFBNO-NSCUHMNNSA-N 4-[(e)-2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-5-iodopyridin-3-yl]ethenyl]-n-methylaniline Chemical group C1=CC(NC)=CC=C1\C=C\C1=CN=C(OCCOCCOCCF)C(I)=C1 MNFDEPKQRJFBNO-NSCUHMNNSA-N 0.000 description 1
- LZDGOLGBOOPIBJ-OWOJBTEDSA-N 4-[(e)-2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-5-iodopyridin-3-yl]ethenyl]phenol Chemical group C1=CC(O)=CC=C1\C=C\C1=CN=C(OCCOCCOCCF)C(I)=C1 LZDGOLGBOOPIBJ-OWOJBTEDSA-N 0.000 description 1
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 1
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010002025 Amyloidosis senile Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 230000007351 Aβ plaque formation Effects 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- NZSQBRZWARZNQH-ZWOACCQCSA-N C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C Chemical compound C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C NZSQBRZWARZNQH-ZWOACCQCSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007509 Cardiac amyloidosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- GDMJWXXHYYWRBX-UHFFFAOYSA-N NC(C(S(=O)O)N)S(=O)O Chemical compound NC(C(S(=O)O)N)S(=O)O GDMJWXXHYYWRBX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 1
- WWFYFEROXYKSLB-NSCUHMNNSA-N [4-[(e)-2-[5-bromo-6-(2-hydroxyethoxy)pyridin-3-yl]ethenyl]phenyl] acetate Chemical group C1=CC(OC(=O)C)=CC=C1\C=C\C1=CN=C(OCCO)C(Br)=C1 WWFYFEROXYKSLB-NSCUHMNNSA-N 0.000 description 1
- ULACWBBZYYDXCU-NSCUHMNNSA-N [4-[(e)-2-[5-bromo-6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]phenyl] acetate Chemical group C1=CC(OC(=O)C)=CC=C1\C=C\C1=CN=C(OCCOCCOCCF)C(Br)=C1 ULACWBBZYYDXCU-NSCUHMNNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- UBSFWQHUDZXPLU-UHFFFAOYSA-N aniline;1,3-benzothiazole Chemical class NC1=CC=CC=C1.C1=CC=C2SC=NC2=C1 UBSFWQHUDZXPLU-UHFFFAOYSA-N 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000006277 halobenzyl group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002975 pon Anatomy 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- REDSKZBUUUQMSK-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC.CCCC[Sn](CCCC)CCCC REDSKZBUUUQMSK-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical class OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、新規のスチリルピリジン化合物、アミロイド−β凝集を診断用に画像化し阻害する上でのその使用及び、これらの化合物の製造方法に関する。
アルツハイマー病(AD)は、認知衰退、不可逆的記憶喪失、失見当及び言語機能障害を特徴とする進行性神経変性障害である。AD脳切片を死後検査することにより、高度にリン酸化されたタンパク質のフィラメントにより形成された数多くの神経原線維のもつれ(NFT)及びアミロイド−β(Aβ)ペプチドから成る豊富な老人斑(SP)が明らかとなる(最近の精査及び付加的引用については、Ginsberg,S.D.,et al.、「アルツハイマー病及び関連疾患の分子病理学」、Cerebral Cortex:Neurodegenerative and Age−related Changes in Structure and Function of Cerebral Cortex中、Kluwer Academic/Plenum,NY(1999年)、pp.603−654;Vogelsberg−Ragaglia,V.,et al、「アルツハイマー病におけるタウの細胞生物学及び細胞骨格病理学」、Alzheimer’s Disease,Lippincot,Williams & Wilkins,Philadelphia,PA(1999年)、pp.359−372)。
本発明は、構造式I、Ia、II及びIIIの新規化合物を提供する。
本発明は、同様に、構造式I、Ia、II及びIIIの放射性標識化合物、医薬として許容される担体又は希釈剤を含む診断用組成物をも提供する。
式I:
nが1〜6の整数であり;A1、A2、A3、A4及びA5のうちの1つ以上3つ以下のものがNであり;その他のものは許容される通りに−CH又は−CR2であり;
R1は、
a.−(CH2)pNRaRb、ここで、Ra及びRbが独立して水素、C1-4アルキル、ヒドロキシ(C1-4)アルキル又はハロ(C1-4)アルキルであり、pが0〜5の整数である;
b.ヒドロキシ、
c.C1-4アルコキシ
d.ヒドロキシ(C1-4)アルキル、
e.ハロゲン、
f.シアノ、
g.水素、
h.ニトロ、
i.(C1−C4)アルキル、
j.ハロ(C1−C4)アルキル、
k.ホルミル、
l.−NHCO(C1-4アルキル)、及び
m.−OCO(C1-4アルキル)、
からなる群から選択され;
i.式:
vi.下記の構造:[ハロ(C1-4)アルキル−O−(C1-4)アルキル]−を有するエーテル(R−O−R)
からなる群から選択され;
A1、A2、A3、A4及びA5のうちの1つ以上3つ以下のものがNであり、その他のものは許容される通りに−CH又は−CR2であり;nが1〜6の整数であり;R1が、以上で記述された全ての有用な値、好ましくはヒドロキシ又はNRaRb(CH2)p−を含み、ここでpは0〜5の整数であり、Ra及びRbは独立して水素、C1-4アルキル又は(CH2)dXであり、Xはハロゲンであり、dは1〜6の整数であり;
i.式:
v.−Ch;及び
vi.−(CH2)w−Ch、ここで、wが1〜10の整数である
からなる群から選択され、
R7及びR8は各々のケースにおいて、水素、ヒドロキシ、アミノ、メチルアミノ、ジメチルアミノ、C1-4アルコキシ、C1-4アルキル及びヒドロキシ(C1-4)アルキルから成る群から独立して選択される。
A1、A2、A3、A4及びA5のうちの1つ以上3つ以下のものがNであり、その他のものは、許容される通りに−CH、−CR2又は−CR3であり;R5及びR5’は独立して水素又はC1-4アルキルであり;R1及びR2は、各ケースにおいて、水素、ハロゲン、C1-4アルキル、シアノ、カルボキシ(C1-5)アルキル、トリフルオロメチル、ニトロ、ハロ(C1-4)アルキル、ホルミル及びNR6R7(CH2)p−(ここで、pは0〜5の整数であり、R6及びR7は独立して水素、C1-4アルキル又は(CH2)dXであり、ここでXは水素であり、dは1〜4の整数である)からなる群から独立して選択され;R1及びR2について以上で列挙した値を加えて、R1及び/又はR2が独立してヒドロキシでもあり得;R3は、水素、ハロゲン、C1-4アルキル、シアノ、カルボキシ(C1-5)アルキル、トリフルオロメチル、ニトロ、ハロ(C1-4)アルキル、ホルミル、NR6R7(CH2)p−(ここで、pは0〜5の整数であり、R6及びR7は独立して水素、C1-4アルキル又は(CH2)dXであり、Xはハロゲンであり、dは1〜4の整数である)、18フルオロメチル、18フルオロエチル、18フルオロプロピル及びSn(アルキル)3からなる群から選択され;
a.C1-4アルキルチオ
b.C1-4アルキルスルホニル、
c.ヒドロキシ、
d.C1-4アルコキシ、
e.pが0〜5の整数であり、R6及びR7が独立して水素、C1-4アルキル又は(CH2)dXであり、ここでXがハロゲンであり、dが1〜4の整数であるものとして、NR6R7(CH2)p−、
f.フェニル(C1-4)アルキル、
g.C6-10アリール、
h.ヘテロアリール、
i.複素環
j.複素環(C1-4)アルキル、及び
k.C3-6シクロアルキル
からなる群から選択され;
i.式:
vi.下記の構造:[ハロ(C1-4)アルキル−O−(C1-4)アルキル]−を有するエーテル(R−O−R)
からなる群から選択され;及び
を含む。
が含まれる。
などのヒドロキシエーテルが含まれる。
(1)任意には乾燥条件にあり、同様に任意には不活性で医薬として許容される担体及び/又は補助物質が添加された、本発明の非放射性標識化合物、及び
(2)還元剤及び任意にはキレート化剤
を含むキットにおいて、成分(1)及び(2)が任意には組合わされていてよく;さらに、過テクネチウム酸溶液の形のテクネチウム99mと成分(1)及び(2)を反応させることにより上述の方法を実施するための処方を伴う使用説明書が任意には含まれていてよい、キットにも関する。
化合物2の合成
(E)−2−クロロ−5−(4−ジメチルアミノスチリル)ピリジン(1)
カリウムtert−ブトキシド(99mg、0.89mmol)を、無水DMF(5.0ml)中のジエチル−(4−ジメチルアミノーベンジル)−ホスホネート(80mg、0.30mmol)の溶液に0℃で添加した。次に2−クロロ−5−ピリジルアルデヒド(42mg、0.30mmol)を加えた。反応混合物を室温まで温め、4時間撹拌した。水を加えて、混合物をMeOH/DCM(1:9、v/v)で抽出した。有機層を分離し、塩水で洗浄し、硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中20%のヘキサン)で精製して、生成物1を得た(48mg、収量:62%)。
水素化ナトリウム(95%、10mg、0.39mmol)を、無水DMF(5.0ml)中の2−(2−(2−フルオロエトキシ)エトキシ)エタノール(39mg、0.26mmol)の溶液に添加した。室温で20分間撹拌した後、化合物5(35mg、0.13mmol)を加え、反応混合物を2時間100℃まで加熱した。室温まで冷却した後、水を加えて、反応混合物を酢酸エチルで抽出した。有機層を分離し、塩水で洗浄し、無水硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中4%のMeOH)で精製して生成物2を得た(16mg、収量;32.9%):
化合物6の合成
(E)−2−クロロ−5−(4−ニトロスチリル)ピリジン(3):
ナトリウムメトキシド(メタノール中1M、5.0ml)を、メタノール(5.0ml)中のジエチル−(4−ニトロ−ベンジル)−ホスホネート(546mg、2.0mmol)及び2−クロロ−5−ピリジルアルデヒド(283mg、2.0mmol)の溶液にゆっくりと添加した。次に反応混合物を1時間還流に付した。0℃まで冷却した後、黄色の沈殿物をろ過し、低温メタノールで洗浄して生成物3を得(458mg、収量:88%)、さらなる精製なく次のステップのために直接使用した。3:
窒素雰囲気の保護下で、2−(2−(2−フルオロエトキシ)エトキシ)−エタノールa(60mg、0.39mmol)を、無水DMF(5ml)中の水素化ナトリウム(26.4mg、鉱油中の60%分散、0.66mmol)の混合物中に0℃で添加した。混合物を30分間室温で撹拌して、化合物3(85.7mg、0.33mmol)を加えた。次に反応混合物を2時間100℃まで加熱し、冷却した。酢酸エチルと水を加え、有機層を分離し、塩水で洗浄し、無水硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中2%のMeOH)で精製し、生成物4を得た(37mg、収量:30%):
化合物4(34mg、0.09mmol)をエタノール(5ml)中に溶解させ、その後塩化第1スズ(51.4mg、0.27mmol)と濃塩酸(0.25ml)を添加した。反応混合物を2時間還流に付し、冷却した。2NのNaOHを使用してpHを10に調整した。ジクロロメタンを加え、有機層を分離し、塩水で洗浄し、無水硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中3%のMeOH)で精製して生成物5を得た(18mg、収量:58%):
ナトリウムメトキシド(メタノール中1M、0.23ml)を、メタノール(5ml)中の化合物5(15.8mg、0.046mmol)の溶液に添加し、その後パラホルムアルデヒド(6.6mg、0.23mmol)を加えた。反応混合物を1.5時間還流に付し、次に氷浴で0℃まで冷却した。ホウ化水素ナトリム(10.4mg、0.27mmol)を慎重に加えた。混合物を再度1時間還流に付して冷却した。ジクロロメタンと水を加え、有機層を分離し、塩水で洗浄して、無水硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中3%MeOH)で精製し生成物6を得た(12mg、収量:73%):
化合物10の合成
(E)−2−(2−(2−(2−ヒドロキシエトキシ)エトキシ)エトキシ)−5−(4−ニトロスチリル)ピリジン(7)
無水DMF(5.0ml)中のトリエチレングリコール(576mg、3.8mmol)と、炭酸カリウム(158.7mg、1.15mmol)、化合物3(100mg、0.38mmol)及びの混合物を、電子レンジで使用可能なバイアル(Biotage製)中に封入し、180℃で25分間マイクロ波照射(Biotage Initiator system)に付した。室温まで冷却した後、水を加えて、反応混合物を酢酸エチルで抽出した。有機層を分離し、塩水で洗浄し、無水硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中4%のMeOH)で精製し、生成物7を得た(110mg、収量:77%):
シアノホウ化水素ナトリウム(36mg、0.57mmol)を、酢酸(10ml)中のパラホルムアルデヒド(57mg、1.9mmol)と化合物8(65mg、0.19mmol)の溶液に添加した。反応混合物を一晩室温で撹拌し、氷の上に注いだ。重炭酸ナトリウムを使用してpHを9に調整した。反応混合物を酢酸エチルで抽出した。有機層を分離し、塩水で洗浄して、無水硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中5%のMeOH)で精製し、生成物9を得た(67mg、収量:95%):
塩化トシル(52mg、0.27mmol)を、0℃で、ピリジン(5.0ml)中の化合物9(43mg、0.116mmol)の溶液に添加した。反応混合物を1時間0℃で撹拌し、次に室温になるまで温めて3時間撹拌した。水を加え、反応混合物を酢酸エチルで抽出した。有機層を分離し、塩水で洗浄して、硫酸ナトリウム上で乾燥させ、蒸発させた。残渣をPTLC(展開溶媒としてDCM中4%のMeOH)で精製し、生成物10を得た(25mg、収量:41%):
化合物11aの合成
a.中間体I8及びI9の合成
2−ヒドロキシ−3−ブロモ−5−ヨードピリジン(I8)
以前に報告された方法(Meana A、et al、Synlett、2003年、1678−1682)に従って、化合物I8を、N−ヨードスクシンイミド(2.48g、11.0mmol)及び3−ブロモ−2−ヒドロキシピリジンI7(1.74g、10.0mmol)から、薄茶色の固体として調製した(2.55g、85%)。
−10℃で、10mLのTHF中のI8(0.393g、1.3mmol)、2−(2−(2−フルオロエトキシ)エトキシ)エタノール(0.200g、1.3mmol)及びPPh3(0.511g,1.95mmol)の撹拌懸濁液に対して、5mLのTHF中のアゾジカルボン酸ジイソプロピル(DIAD、0.394g、1.95mmol)を滴下により添加した。氷塩水浴を除去して、反応を2時間室温(r.t.)に保った。反応溶液を濃縮して、FC(MeOH/CHCl3、1/99)により精製し、無色の粘性液体であるI9を得た(0.423g、75%)。
(E)−(5−ブロモ−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−(4−ジメチルアミノフェニル)−エチレン(11a)
2mLのDMF中の、4−ジメチルアミノスチレン(0.110g、0.75mmol)、I9(0.217g、0.5mmol)、K2CO3(0.173g、1.25mmol)、テトラブチルアンモニウムブロミド(TBAB、0.322g、1.0mmol)及び酢酸パラジウム(Pd(OAc)2、0.006g、0.025mmol)の混合物を、15分間窒素でパージすることにより脱酸素し、その後2時間65℃まで加熱した。反応混合物を室温まで冷却して、酢酸エチル(EtOAc)での標準精密処理に付した。粗生成物をFC(EtOAc/ヘキサン、30/70)により精製し、その結果明黄色の固体として11aを得た(0.178g、79%)。
化合物11bの合成
(E)−(5−ブロモ−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−(4−メチルアミノフェニル)−エチレン(11b)
化合物11bを、4−メチルアミノスチレン(0.073g、0.55mmol)及びI9(0.217g、0.50mmol)から、明黄色の粘性液体として調製した(0.113g、収量52%)。
化合物11eの合成
(E)−(5−ブロモ−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−[4−N−メチル−4−N−(tert−ブチルオキシカルボニル)アミノフェニル]−エチレン(11c)
化合物11cを、4−N−メチル−4−N−(tert−ブチルオキシカルボニル)アミノスチレン(0.219g、0.94mmol)及びI9(0.273g、0.63mmol)から、白色の粘性液体として調製した(0.319g、収量94%)。
4−アセトキシスチレン(0.122g、0.75mmol)及びI9(0.217g、0.5mmol)から、白色の粘性液体として化合物11dを調製した(0.181g、収量77%)。
酢酸塩11d(0.145g、0.31mmol)及びK2CO3(0.064g、0.465mmol)をEtOH/THF(5mL/5mL)中に入れ、反応混合物を2時間室温で撹拌した。EtOAcでの標準精密処理の後、粗生成物をPTLCで精製して、白色の固体として11eを得た(0.128g、97%)。
化合物12bの合成
(E)−(5−トリ−ブチルスタンニル−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−(4−メチルアミノフェニル)−エチレン(12b)
11b(0.069g、0.156mmol)から、明黄色の油として化合物12bを調製した(0.068g、68%収量)。
化合物12eの合成
(E)−(5−トリ−ブチルスタンニル−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−(4−ヒドロキシフェニル)−エチレン(12e)
化合物12eを、11e(0.032g、0.075mmol)から白色の粘性液体として調製した(0.040g、84%収量)。
化合物13aの合成
(E)−(5−トリ−ブチルスタンニル−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−(4−ジメチルアミノフェニル)−エチレン(12a)
トルエン中の、11a(0.052g、0.115mmol)、ビス(トリブチルスズ)((Bu3Sn)2、0.333g、0.57mmol)及ビパラジウムテトラキストリフェニルホスフィン(Pd(PPh3)4、0.013g、10mol%)の混合物を、18時間110℃で加熱した。反応溶液を室温まで冷却し、5mLの10%KFで処理した。さらに0.5時間勢いよく撹拌した後に、EtOAcとそれに続くFC(EtOAc/ヘキサン、25/75)での標準精密処理により、明黄色の油として12aを得た(0.052g、68%)。
THF(2mL)中のヨウ素(I2、0.063g、0.24mmol)の溶液を、THF(3mL)中の12a(0.114g、0.172mmol)の氷浴冷却済の溶液に滴下により添加した。添加後、反応を1時間0℃で撹拌した。CH2Cl2を用いた標準精密処理の後、粗生成物をFC(EtOAc/ヘキサン、25/75)により精製して、明黄色固体13aを得た(0.037g、48%)。
化合物13bの合成
(E)−(5−トリ−ブチルスタンニル−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−[4−N−メチル−4−N−(tert−ブチルオキシカルボニル)アミノフェニル]−エチレン(12c)
化合物12cを、11c(0.072g、0.133mmol)から白色の粘性液体として調製した(0.077g、77%収量)。
化合物13cを、12c(0.024g、0.032mmol)から白色の粘性液体として調製した(0.018g、98%)。
0℃の、2mLのCH2Cl2中の13c(0.014g、0.024mmol)及び2,6−ルチジン(28μL、0.24mmol)の撹拌溶液に対して、トリメチルシリルトリフラート(34μL、0.19mmol)を添加した。15分後、反応溶液をCH2Cl2での標準精密処理に付した。粗生成物をPTLCで精製して、明黄色粘性液体の13bを得た(0.010g、88%)。
化合物13eの合成
(E)−(5−トリ−ブチルスタンニル−6−{2−[2−(2−フルオロエトキシ)エトキシ]エトキシ}ピリジン−3−イル)−2−(4−ヒドロキシフェニル)−エチレン(12e)
化合物12eを、11e(0.032g、0.075mmol)から白色の粘性液体(0.040g、84%収量)として調製した。
化合物13eを、12e(0.012g、0.019mmol)から白色固体として調製した(0.008g、90%)。
化合物14aの合成
2−ヒドロキシエトキシ−3−ブロモ−5−ヨードピリジン(9b)
化合物14aを、4−ジメチルアミノスチレン(0.031g、0.212mmol)及びI10(0.073g、0.212mmol)から明黄色の固体として調製した(0.022g、29%収量)。
化合物14bの合成
(E)−[5−ブロモ−6−(2−ヒドロキシエトキシ)ピリジン−3−イル]−2−(4−メチルアミノフェニル)−エチレン(14b)
化合物14bを、4−メチルアミノスチレン(0.140g,1.05mmol)及び110(0.241g、0.7mmol)から明黄色の粘性液体として調製した(0.149g、61%収量)。
化合物14dの合成
(E)−[5−ブロモ−6−(2−ヒドロキシエトキシ)ピリジン−3−イル]−2−(4−アセトキシフェニル)−エチレン(14d)
化合物14eの合成
(E)−[5−ブロモ−6−(2−ヒドロキシエトキシ)ピリジン−3−イル]−2−(4−ヒドロキシフェニル)−エチレン(14e)
11eの調製に記述されているような類似の手順において、化合物14eを、酢酸塩14d(0.031g、0.082mmol)から白色固体として調製した(0.020g、73%)。
化合物15eの合成
(E)−[5−トリ−ブチルスタンニル−6−(2−ヒドロキシエトキシ)ピリジン−3−イル]−2−(4−ヒドロキシフェニル)−エチレン(15e)
化合物I5eを、14e(0.031g、0.092mmol)から白色の粘性液体として調製した(0.012g、24%収量)。
化合物16aの合成
(E)−[5−トリ−ブチルスタンニル−6−(2−ヒドロキシエトキシ)ピリジン−3−イル]−2−(4−ジメチルアミノフェニル)−エチレン(15a)
化合物15aを、14a(0.100g、0.275mmol)から明黄色の油として調製した(0.105g、66%収量)。
化合物16aを、15a(0.011g、0.019mmol)から、明黄色の固体として調製した(0.004g、50%)。
化合物16bの合成
(E)−[5−トリ−ブチルスタンニル−6−(2−ヒドロキシエトキシ)ピリジン−3−イル]−2−(4−メチルアミノフェニル)−エチレン(15b)
化合物15bを、14b(0.052g、0.15mmol)から明黄色の油として調製した(0.059g、64%収量)。
放射性ヨウ素化
放射性ヨウ素化された化合物[125I]13a、13b、16a、16b及び16eを、以前に記述された方法(参考)に従って対応するトリブチルチン前駆体からヨード脱スタニル化反応を介して調製した。過酸化水素(50μL、3%w/v)を封入したバイアル中で50μLのトリブチルチン前駆体(4μg/μLEtOH)、50μLの1NのHcl及び[125I]NaI(PerkinElmerより購入した1〜5mCi)の混合物に添加した。反応を5〜10分間室温で進行させ、飽和NaHSO3を100μL添加することで終結させた。1.5mLの飽和重炭酸ナトリウム溶液での中和の後、酢酸エチル(3×1mL)で反応混合物を抽出した。組合された抽出物を、乾燥するまで蒸発させた。100μLのEtOH中で残渣を溶解させ、逆相カラムを用いてHPLCにより精製した(Phenomenex Gemini C18分析カラム、4.6×250mm、5μm、CH3CN/ギ酸アンモニウム緩衝液(1mM)8/2又は7/3;流速0.5〜1.0mL/分)。担体無添加の生成物を乾燥に至るまで蒸発させ、100%のEtOH(1μCi/μL)中で再度溶解させ、これを動物研究及びオートラジオグラフィ研究のため最高6週間−20℃で保管した。
結合試験
標準ヨード脱スタニル化反応を用いて、2,200Ci/mmolの非活性及び95%超の放射化学的純度をもつ[125I]IMPYを調製し、Kung、M.−P−;Hou、C;Zhuang、Z.−P.;Cross.A.J.:Maier、D.L;Kung、H.F.、「2重トランスジェニックPSAPPマウスにおけるb−アミロイド斑のための潜在的造影剤としてのIMPYの特徴づけ」Eur.J.Nucl.Med.Mol.Imaging、2004年、31、1136−1145、の中で以前に記述されている通り、単純化されたC−4ミニカラムにより精製した。競合結合検定を、12×75mmのホウケイ酸ガラス管の中で実施した。反応混合物は、1mlの最終体積中に50μlのプールされたAD脳ホモジネート(20〜50μg)、50μlの[125I]IMPY(PBS中で希釈された0.04〜0.06nM)及び50μlの阻害物質(0.1%のウシ血清アルブミンを含有するPBS中で連続希釈された10-5〜10-10M)を含有していた。同じ検定管の中で600nMIMPYの存在下で非特異的結合を定義づけした。混合物を2時間37℃でインキュベートし、結合及び遊離放射能を、BrandelM−24R細胞収穫装置を用いたWhatmanGF/Bフィルタを通した真空ろ過によって分離し、その後室温でPBS3mlで2回洗浄した。結合I−125リガンドを含有するフィルタを、70%の計数効率をもつガンマ計数器(Packard5000)の中で計数した。検定条件の下で、特異的に結合した画分は、合計放射能の15%未満であった。阻害実験の結果を、Ki値の計算のもととなった平衡結合データ分析を用いた非線形回帰分析に付した。図1及び6は、本発明の選択された化合物についてのKi値を示している。
フィルムオートラジオグラフィ
[18F]トレーサ:粉末化されたドライアイス内で脳を凍結させることにより、AD対象由来の脳切片を得、厚み20マイクロメートルの切片に切断した。室温で1時間、切片を[18F]トレーサ(200,000〜250,000cpm/200μl)と共にインキュベートした。その後、切片を40%のEtOH中の飽和Li2CO3内に浸漬し(2回の2分間洗浄)、40%のEtOHで洗浄し(1回の2分間洗浄)、その後30秒間水で洗い流した。乾燥後に、18F標識した切片をコダックMRフィルムに一晩曝露した。結果は図2内のフィルム中に描かれている。
マウス内の器官分布
イソフルラン麻酔下にある間に、[125I]トレーサ(5〜10μCi)を含有する0.1%のウシ血清アルブンミン溶液0.15mLを直接、ICRマウス(22〜25g、雄)の尾静脈の中に注入した。注入後の指定された時点で、頚椎脱臼によりマウス(各時点についてn=3)を屠殺した。関心対象の器官を取り出し、計量し、放射能を自動ガンマ計数器で計数した。器官1個あたりの百分率用量を、注入された材料の適切な希釈されたアリコートに対する組織計数の比較によって計算した。血液の総活性を、それが合計体重の7%であるという仮定の下で計算した。標本1gあたりの%用量を、希釈した初期用量の計数と標本計数の比較により計算した。
Claims (12)
- qが3または4である、請求項1に記載の化合物。
- R a がメチルであり、そしてR b が水素である、請求項1に記載の化合物。
- 請求項1〜8のいずれか1項に記載の放射性標識化合物を含む、アミロイド沈着を画像化するための診断用組成物。
- 哺乳動物におけるアミロイド沈着を画像化する方法において使用される、請求項9に記載の診断用組成物であって、前記方法が、
a.検出可能な量の前記診断用組成物を導入された哺乳動物において、標識化合物をアミロイド沈着と会合させるのに充分な時間を与える段階;
b.単数又は複数のアミロイド沈着と会合された標識化合物を検出する段階
を含む、前記診断用組成物。 - 哺乳動物におけるアミロイド沈着を画像化する方法において使用される、請求項11に記載の診断用組成物であって、前記方法が、
a.検出可能な量の前記診断用組成物を導入された哺乳動物において、標識化合物をアミロイド沈着と会合させるのに充分な時間を与える段階;
b.単数又は複数のアミロイド沈着と会合された標識化合物を検出する段階
を含む、前記診断用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78715606P | 2006-03-30 | 2006-03-30 | |
US60/787,156 | 2006-03-30 | ||
PCT/US2007/007400 WO2007126733A2 (en) | 2006-03-30 | 2007-03-26 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009532349A JP2009532349A (ja) | 2009-09-10 |
JP5290954B2 true JP5290954B2 (ja) | 2013-09-18 |
Family
ID=38326579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009502912A Active JP5290954B2 (ja) | 2006-03-30 | 2007-03-26 | スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用 |
Country Status (34)
Country | Link |
---|---|
US (3) | US7687052B2 (ja) |
EP (3) | EP1999109B1 (ja) |
JP (1) | JP5290954B2 (ja) |
KR (1) | KR101376807B1 (ja) |
CN (1) | CN101522624B (ja) |
AT (1) | ATE539060T1 (ja) |
AU (1) | AU2007243712B2 (ja) |
BR (1) | BRPI0710225B1 (ja) |
CA (1) | CA2644530C (ja) |
CR (1) | CR10329A (ja) |
CY (3) | CY1113048T1 (ja) |
DK (2) | DK2363392T3 (ja) |
EA (1) | EA017898B1 (ja) |
EC (1) | ECSP088783A (ja) |
ES (2) | ES2628882T3 (ja) |
FR (1) | FR13C0034I2 (ja) |
GT (1) | GT200800201A (ja) |
HR (2) | HRP20120135T1 (ja) |
HU (2) | HUE032660T2 (ja) |
IL (1) | IL193567A (ja) |
LT (1) | LT2363392T (ja) |
LU (1) | LU92232I2 (ja) |
MX (1) | MX2008012527A (ja) |
NO (2) | NO342090B1 (ja) |
NZ (1) | NZ570887A (ja) |
PL (2) | PL2363392T3 (ja) |
PT (2) | PT2363392T (ja) |
RS (2) | RS56171B1 (ja) |
SG (1) | SG173338A1 (ja) |
SI (2) | SI1999109T1 (ja) |
TW (1) | TWI399366B (ja) |
UA (1) | UA97802C2 (ja) |
WO (1) | WO2007126733A2 (ja) |
ZA (1) | ZA200807955B (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2363392T3 (pl) | 2006-03-30 | 2017-10-31 | Univ Pennsylvania | Styrylopirydynowe pochodne i ich zastosowanie do wiązania i obrazowania płytek amyloidowych |
EP2172444A4 (en) * | 2007-07-04 | 2010-12-22 | Univ Tohoku | PET SENSOR HAVING ALCOXY GROUP SUBSTITUTED BY FLUORIN ATOM AND HYDROXY GROUP |
JP5603855B2 (ja) * | 2008-04-04 | 2014-10-08 | アビッド レディオファーマシューティカルズ、インク. | 神経変成疾患の放射性薬剤による画像化 |
EA023014B1 (ru) * | 2008-12-31 | 2016-04-29 | Эвид Рэйдиофармасьютикалз, Инк. | Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции |
WO2011003591A1 (en) * | 2009-07-10 | 2011-01-13 | Bayer Schering Pharma Aktiengesellschaft | Usage of low to medium-pressure liquid chromatography for the purification of radiotracers |
WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
EP2515948A1 (en) * | 2009-12-23 | 2012-10-31 | Piramal Imaging SA | Formulations suitable for pet imaging with hydrophobic pet agents |
BR112012030935B1 (pt) | 2010-04-06 | 2020-11-17 | Life Molecular Imaging Sa | método para a produção de ligantes de beta-amiloide marcados com f-18 |
WO2011141515A1 (en) | 2010-05-14 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Diagnostic agents for amyloid beta imaging |
KR20130088118A (ko) * | 2010-06-04 | 2013-08-07 | 피라말 이미징 에스에이 | F-18 표지된 아밀로이드 베타 리간드의 제조 방법 |
TWI504414B (zh) | 2010-06-04 | 2015-10-21 | Bayer Schering Pharma Ag | 生產F-18標記之Aβ配位體之方法 |
CA2801534A1 (en) | 2010-06-04 | 2011-12-08 | Piramal Imaging Sa | Method for production of f-18 labeled amyloid beta ligand |
CN101891674B (zh) * | 2010-06-24 | 2012-11-14 | 山东大学 | 4-苯乙烯基吡啶类化合物及其制备方法与应用 |
US9259495B2 (en) * | 2010-10-12 | 2016-02-16 | Mayo Foundation For Medical Education And Research | Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives |
US20140079635A1 (en) * | 2011-03-30 | 2014-03-20 | Case Western Reserve University | Molecular probes for detecting lipid composition |
CN106729771A (zh) | 2011-04-21 | 2017-05-31 | 加利福尼亚大学董事会 | 官能化磁性纳米颗粒及在淀粉样沉积物和神经原纤维缠结成像中用途 |
EP2768790A1 (en) | 2011-10-19 | 2014-08-27 | Piramal Imaging SA | IMPROVED METHOD FOR PRODUCTION OF F-18 LABELED Aß LIGANDS |
JP6207588B2 (ja) | 2012-04-10 | 2017-10-04 | ランセウス メディカル イメージング, インコーポレイテッド | 放射性薬剤合成方法 |
JP6099045B2 (ja) * | 2013-04-30 | 2017-03-22 | 国立大学法人京都大学 | トリアゾロピリミジン誘導体化合物 |
JP6041751B2 (ja) * | 2013-05-07 | 2016-12-14 | 日本メジフィジックス株式会社 | スチリルピリジン誘導体化合物 |
JP2014218454A (ja) * | 2013-05-07 | 2014-11-20 | 日本メジフィジックス株式会社 | スチリルピリジン誘導体化合物 |
CN103645254B (zh) * | 2013-11-28 | 2015-01-07 | 江苏省原子医学研究所 | 一种Aβ斑块显像剂前体AV45的含量分析方法 |
JP6529986B2 (ja) | 2014-05-13 | 2019-06-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 重水素化ヘテロ環式化合物及びイメージング剤としてのその使用 |
US10478513B2 (en) | 2015-08-18 | 2019-11-19 | The Regents Of The University Of Califonia | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
CN109400615B (zh) * | 2017-08-18 | 2021-07-16 | 上海交通大学医学院附属新华医院 | 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用 |
CN108299287A (zh) * | 2018-01-02 | 2018-07-20 | 北京师范大学 | 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物 |
CN114805190A (zh) * | 2022-06-08 | 2022-07-29 | 吉林大学第一医院 | 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法 |
WO2024107620A1 (en) | 2022-11-14 | 2024-05-23 | Eli Lilly And Company | Polymorphic forms of florbetapir precursor av-105 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992000963A1 (en) * | 1990-07-12 | 1992-01-23 | Yoshitomi Pharmaceutical Industries, Ltd. | Styryl compounds and use thereof as medicine |
JPH0545875A (ja) * | 1991-08-08 | 1993-02-26 | Konica Corp | 感光性組成物 |
US6020436A (en) | 1993-03-09 | 2000-02-01 | The Chromaline Corporation | Photosensitive resin composition |
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
EP1266884A4 (en) * | 2000-03-22 | 2003-04-23 | Bf Res Inst Inc | IMAGE DIAGNOSIS PROBE, BASED ON SUBSTITUTED AZOBENZOL OR ITS ANALOGA, FOR DISEASES WHICH ARE ATTRIBUTED TO AMYLOID ACCUMULATION, AND MIXTURES CONTAINING THIS IMAGE |
US8007954B2 (en) | 2000-11-09 | 2011-08-30 | The Trustees Of The University Of Pennsylvania | Use of sulfur-containing fuels for direct oxidation fuel cells |
JP2002182254A (ja) | 2000-12-18 | 2002-06-26 | Fuji Photo Film Co Ltd | 非線形光学材料とその製造方法 |
JP4436928B2 (ja) * | 2001-08-27 | 2010-03-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | スチルベン誘導体、およびアミロイド斑の結合および画像化のためのその使用 |
JP2005529464A (ja) | 2002-06-06 | 2005-09-29 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | セラミックアノード及びそれを生産する方法 |
WO2004016271A1 (en) * | 2002-08-14 | 2004-02-26 | Axxima Pharmaceuticals Ag | Pyrimidones as antiviral agents |
JP4482352B2 (ja) | 2004-03-11 | 2010-06-16 | 本田技研工業株式会社 | 固体高分子型燃料電池 |
SI2213652T1 (sl) * | 2004-12-17 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov |
WO2006078384A2 (en) * | 2004-12-17 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use |
US20070031328A1 (en) * | 2005-06-24 | 2007-02-08 | Kung Hank F | Radiolabeled-pegylation of ligands for use as imaging agents |
PL2363392T3 (pl) * | 2006-03-30 | 2017-10-31 | Univ Pennsylvania | Styrylopirydynowe pochodne i ich zastosowanie do wiązania i obrazowania płytek amyloidowych |
US20080253967A1 (en) | 2007-04-13 | 2008-10-16 | Kung Hank F | Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques |
-
2007
- 2007-03-26 PL PL11152124T patent/PL2363392T3/pl unknown
- 2007-03-26 CN CN2007800116909A patent/CN101522624B/zh active Active
- 2007-03-26 CA CA2644530A patent/CA2644530C/en active Active
- 2007-03-26 DK DK11152124.1T patent/DK2363392T3/en active
- 2007-03-26 LT LTEP11152124.1T patent/LT2363392T/lt unknown
- 2007-03-26 EP EP07753982A patent/EP1999109B1/en active Active
- 2007-03-26 UA UAA200812698A patent/UA97802C2/uk unknown
- 2007-03-26 ES ES11152124.1T patent/ES2628882T3/es active Active
- 2007-03-26 EP EP11152115A patent/EP2363391A1/en not_active Withdrawn
- 2007-03-26 PL PL07753982T patent/PL1999109T3/pl unknown
- 2007-03-26 SI SI200730865T patent/SI1999109T1/sl unknown
- 2007-03-26 WO PCT/US2007/007400 patent/WO2007126733A2/en active Application Filing
- 2007-03-26 PT PT111521241T patent/PT2363392T/pt unknown
- 2007-03-26 SI SI200731938T patent/SI2363392T1/sl unknown
- 2007-03-26 AT AT07753982T patent/ATE539060T1/de active
- 2007-03-26 EA EA200870389A patent/EA017898B1/ru not_active IP Right Cessation
- 2007-03-26 BR BRPI0710225-9A patent/BRPI0710225B1/pt active IP Right Grant
- 2007-03-26 EP EP11152124.1A patent/EP2363392B1/en active Active
- 2007-03-26 HU HUE11152124A patent/HUE032660T2/en unknown
- 2007-03-26 NZ NZ570887A patent/NZ570887A/en unknown
- 2007-03-26 PT PT07753982T patent/PT1999109E/pt unknown
- 2007-03-26 ES ES07753982T patent/ES2378785T3/es active Active
- 2007-03-26 US US11/727,401 patent/US7687052B2/en active Active
- 2007-03-26 RS RS20170578A patent/RS56171B1/sr unknown
- 2007-03-26 MX MX2008012527A patent/MX2008012527A/es active IP Right Grant
- 2007-03-26 RS RS20120077A patent/RS52222B/en unknown
- 2007-03-26 DK DK07753982.3T patent/DK1999109T3/da active
- 2007-03-26 SG SG2011048477A patent/SG173338A1/en unknown
- 2007-03-26 AU AU2007243712A patent/AU2007243712B2/en active Active
- 2007-03-26 JP JP2009502912A patent/JP5290954B2/ja active Active
- 2007-04-26 TW TW096114833A patent/TWI399366B/zh active
-
2008
- 2008-08-05 US US12/186,072 patent/US8506929B2/en active Active
- 2008-08-20 IL IL193567A patent/IL193567A/en active IP Right Grant
- 2008-09-16 ZA ZA2008/07955A patent/ZA200807955B/en unknown
- 2008-09-29 KR KR1020087023884A patent/KR101376807B1/ko active IP Right Grant
- 2008-09-30 EC EC2008008783A patent/ECSP088783A/es unknown
- 2008-09-30 CR CR10329A patent/CR10329A/es unknown
- 2008-09-30 GT GT200800201A patent/GT200800201A/es unknown
- 2008-10-29 NO NO20084590A patent/NO342090B1/no active Protection Beyond IP Right Term
-
2012
- 2012-02-10 HR HR20120135T patent/HRP20120135T1/hr unknown
- 2012-03-07 CY CY20121100225T patent/CY1113048T1/el unknown
-
2013
- 2013-01-07 US US13/735,609 patent/US8840866B2/en active Active
- 2013-06-26 FR FR13C0034C patent/FR13C0034I2/fr active Active
- 2013-06-26 LU LU92232C patent/LU92232I2/fr unknown
- 2013-06-27 CY CY2013024C patent/CY2013024I1/el unknown
- 2013-06-27 HU HUS1300028C patent/HUS1300028I1/hu unknown
-
2017
- 2017-06-06 HR HRP20170857TT patent/HRP20170857T1/hr unknown
- 2017-06-22 CY CY20171100664T patent/CY1119048T1/el unknown
-
2018
- 2018-09-11 NO NO2018030C patent/NO2018030I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5290954B2 (ja) | スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用 | |
AU2008203856B8 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
AU2002323417A1 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
JP2010524965A (ja) | ジフェニル−ヘテロアリール誘導体並びにアミロイド斑への結合及び画像化のためのその使用 | |
CA2672187A1 (en) | Acetylene derivatives and their use for binding and imaging amyloid plaques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100202 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130403 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130606 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5290954 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |